Significant Leadership Changes at Avet Pharma with New CEO Transition Announced

Leadership Transition at Avet Pharma

Avet Pharma has made a noteworthy announcement regarding a significant leadership change within the organization. On February 4, 2026, the company revealed that its long-serving President and Chief Executive Officer, George Svokos, will retire on April 3, 2026. This decision comes after a successful tenure where Svokos led the company through a multi-year turnaround and substantial operational improvements.

With Svokos's planned departure, he will transition to a role on Avet’s Board of Directors, ensuring continuity and guidance during this transitional period. The news of his retirement marks the end of an era for Avet Pharma, as Svokos has been an integral part of the company’s journey toward operational excellence and growth.

In tandem with this leadership change, Avet Pharma has announced the promotion of Dan Lukasiewicz to Chief Commercial Officer (CCO). Lukasiewicz's previous contributions to the firm have been paramount, particularly in driving the company’s recent growth and modernizing its commercial strategy. His experience and insight make him a fitting choice to lead the commercial organization during this pivotal moment for Avet.

Vikas Thapar, Chairman of the Board, expressed confidence in Lukasiewicz's capabilities, stating, “Dan's deep institutional knowledge and proven track record of driving revenue and building high-performing teams make him the natural choice to lead our commercial organization.” Following his promotion, Lukasiewicz emphasized his commitment to maintaining momentum and ensuring that Avet Pharma remains a reliable partner for its customers. He stated, “I am fully committed to accelerating our momentum. Our focus is clear—we will continue to be a reliable, agile partner to our customers while aggressively expanding our portfolio and market presence.”

The leadership transition comes at an important time for Avet Pharma, a specialty generic pharmaceutical company based in East Brunswick, New Jersey. Avet focuses on the development, manufacturing, and marketing of both generic and legacy branded pharmaceutical products for the U.S. prescription market. Since its inception, the company has expanded its product portfolio to over 150 items across various therapeutic categories, including oncology, cardiovascular, metabolic diseases, anti-infectives, and pain management.

Under the leadership of its new CCO, Avet Pharma aims to continue its trajectory of expansion and innovation. The company prides itself on providing high-quality and affordable medicines to its customers, whether dealing with simple oral solid products or more complex injectables.

As George Svokos steps down, Avet Pharma’s board and employees express profound gratitude for his contributions and leadership over the years. The company is confident that Dan Lukasiewicz will steer its commercial strategies effectively, helping to fulfill Avet Pharma's vision of becoming a key player in the generic pharmaceutical landscape.

In conclusion, the leadership changes at Avet Pharma reflect the company’s commitment to growth and adaptability in an ever-changing pharmaceutical environment. With Dan Lukasiewicz now at the helm of the commercial operations, stakeholders can look forward to an exciting phase marked by innovation and strategic expansion. The board’s faith in Lukasiewicz signifies their confidence in him to uphold and further the legacy of George Svokos, ensuring that Avet Pharma is poised to face future challenges head-on.